Polygenic Risk Scores for Personalized Cardiovascular Pharmacogenomics―A Scoping Review DOI Creative Commons
Aeshita Dwivedi, Jobanjit Phulka,

Peyman Namdarimoghaddam

et al.

Scientia Pharmaceutica, Journal Year: 2025, Volume and Issue: 93(2), P. 18 - 18

Published: April 8, 2025

Cardiovascular disease (CVD) is the leading cause of mortality worldwide, often involving a strong genetic background. Polygenic risk scores (PRSs) combine cumulative effects multiple variants to quantify an individual’s susceptibility CVD. Pharmacogenomics (PGx) can further personalize treatment by tailoring medication choices profile. Even with these potential benefits, extent which PRS be integrated into PGx CVD remains unclear. Our review provides overview current evidence on application in CVD, examining clinical utility and limitations providing directions for future research. Following Preferred Reporting Items Systematic Reviews Meta-Analyses extension Scoping protocol, we conducted comprehensive literature search PubMed, EMBASE, Web Science. Studies investigating relationship between predicting efficacy, adverse effects, or cost-effectiveness cardiovascular medications were selected. Of 1894 articles identified, 32 met inclusion criteria. These studies predominantly examined lipid-lowering therapies, antihypertensives, antiplatelets, although other classes (e.g., rate-control drugs, ibuprofen/acetaminophen, diuretics, antiarrhythmics) also included. findings showed that most robustly validated especially statins, where reported individuals higher PRSs derived greatest reduction lipids while statins. analyzing antiarrhythmic demonstrated more variable outcomes, though certain did identify subgroups significantly improved response rates events. Though was tool many cases, found some key its applicability research, such as under-representation non-European-ancestry cohorts lack standardized outcome reporting. In conclusion, offers promise improving efficacy enhancing personalization individual level, several obstacles, need including broader ancestral diversity robust data remain. Future research must (i) prioritize validating ethnically diverse populations, (ii) refine derivation methods tailor them drug phenotypes, (iii) establish clear attainable guidelines standardizing reporting outcomes.

Language: Английский

Polygenic Risk Scores for Personalized Cardiovascular Pharmacogenomics―A Scoping Review DOI Creative Commons
Aeshita Dwivedi, Jobanjit Phulka,

Peyman Namdarimoghaddam

et al.

Scientia Pharmaceutica, Journal Year: 2025, Volume and Issue: 93(2), P. 18 - 18

Published: April 8, 2025

Cardiovascular disease (CVD) is the leading cause of mortality worldwide, often involving a strong genetic background. Polygenic risk scores (PRSs) combine cumulative effects multiple variants to quantify an individual’s susceptibility CVD. Pharmacogenomics (PGx) can further personalize treatment by tailoring medication choices profile. Even with these potential benefits, extent which PRS be integrated into PGx CVD remains unclear. Our review provides overview current evidence on application in CVD, examining clinical utility and limitations providing directions for future research. Following Preferred Reporting Items Systematic Reviews Meta-Analyses extension Scoping protocol, we conducted comprehensive literature search PubMed, EMBASE, Web Science. Studies investigating relationship between predicting efficacy, adverse effects, or cost-effectiveness cardiovascular medications were selected. Of 1894 articles identified, 32 met inclusion criteria. These studies predominantly examined lipid-lowering therapies, antihypertensives, antiplatelets, although other classes (e.g., rate-control drugs, ibuprofen/acetaminophen, diuretics, antiarrhythmics) also included. findings showed that most robustly validated especially statins, where reported individuals higher PRSs derived greatest reduction lipids while statins. analyzing antiarrhythmic demonstrated more variable outcomes, though certain did identify subgroups significantly improved response rates events. Though was tool many cases, found some key its applicability research, such as under-representation non-European-ancestry cohorts lack standardized outcome reporting. In conclusion, offers promise improving efficacy enhancing personalization individual level, several obstacles, need including broader ancestral diversity robust data remain. Future research must (i) prioritize validating ethnically diverse populations, (ii) refine derivation methods tailor them drug phenotypes, (iii) establish clear attainable guidelines standardizing reporting outcomes.

Language: Английский

Citations

0